NASDAQ:CMRA Comera Life Sciences (CMRA) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free CMRA Stock Alerts $0.04 0.00 (-11.95%) (As of 01:18 PM ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0652-Week Range$0.02▼$0.83Volume267 shsAverage Volume21,568 shsMarket Capitalization$1.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Comera Life Sciences alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Comera Life Sciences Stock (NASDAQ:CMRA)Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Read More CMRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRA Stock News HeadlinesJanuary 31, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.January 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionDecember 6, 2023 | msn.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Announces Process Exploring Strategic AlternativesNovember 26, 2023 | benzinga.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 14, 2023 | finance.yahoo.comComera Life Sciences Designates Dorothy Clarke to Board of DirectorsApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.November 13, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 9, 2023 | msn.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | finance.yahoo.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsOctober 18, 2023 | finance.yahoo.comComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 16, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceSeptember 13, 2023 | benzinga.comMassive Insider Trade At Comera Life SciencesSeptember 12, 2023 | benzinga.com10% Owner At This Health Care Company Buys $1.05M of StockSeptember 12, 2023 | finance.yahoo.comComera Life Sciences Announces the Completion of $4.1 Million Private PlacementAugust 16, 2023 | finance.yahoo.comComera Study Shows Caffeine’s Ability to Reduce Viscosity in AntibodiesAugust 16, 2023 | finance.yahoo.comComera Life Sciences Announces Publication of Study Reinforcing Caffeine’s Viscosity Reducing CapabilitiesAugust 10, 2023 | finance.yahoo.comComera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business HighlightsAugust 8, 2023 | finance.yahoo.comComera Life Sciences Boosts SQore Platform PatentsAugust 8, 2023 | finance.yahoo.comComera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ PlatformAugust 2, 2023 | finance.yahoo.comComera Life Sciences Announces $4.1 Million Private PlacementAugust 1, 2023 | finance.yahoo.comComera Life Sciences Announces $4.1 Million Private PlacementJuly 24, 2023 | finance.yahoo.comComera Partners with Quality Chemical Laboratories to Strengthen Supply ChainJuly 15, 2023 | seekingalpha.comCMRA Comera Life Sciences Holdings, Inc.May 11, 2023 | finance.yahoo.comComera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business HighlightsSee More Headlines Receive CMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Comera Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMRA CUSIPN/A CIK1907685 Webcomeralifesciences.com Phone617-871-2101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,000,000.00 Net Margins-904.00% Pretax Margin-901.00% Return on EquityN/A Return on Assets-297.91% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual Sales$630,000.00 Price / Sales1.76 Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / Book-0.10Miscellaneous Outstanding Shares30,740,000Free Float28,002,000Market Cap$1.11 million OptionableNot Optionable Beta0.37 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Michael G. Campbell CPA (Age 55)CEO, CFO & Principal Accounting Officer Comp: $269.11kDr. David Soane Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Janice Marie McCourt B.S. (Age 62)CLP, M.B.A., R.Ph., Chief Business Officer Key CompetitorsSunshine BiopharmaNASDAQ:SBFMGRI BioNASDAQ:GRIPanbela TherapeuticsNASDAQ:PBLABiodexa PharmaceuticalsNASDAQ:BDRXHistogenNASDAQ:HSTOView All CompetitorsInsidersCharles CheringtonBought 2,053,789 shares on 9/11/2023Total: $1.05 M ($0.51/share)Robert Patrick MahoneyBought 20,000 shares on 8/14/2023Total: $12,600.00 ($0.63/share)David SoaneBought 273,838 shares on 7/31/2023Total: $139,657.38 ($0.51/share)View All Insider Transactions CMRA Stock Analysis - Frequently Asked Questions How have CMRA shares performed in 2024? Comera Life Sciences' stock was trading at $0.0550 on January 1st, 2024. Since then, CMRA stock has decreased by 34.4% and is now trading at $0.0361. View the best growth stocks for 2024 here. How do I buy shares of Comera Life Sciences? Shares of CMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMRA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
